VEA
PHAT icon

Virtus ETF Advisers’s Phathom Pharmaceuticals PHAT Stock Holding History

Virtus ETF Advisers’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-43,789
Closed -$356K – 690
2024
Q4 		$356K Buy
43,789
+13,711
+46% +$170K 0.15% 196
2024
Q3 		$544K Hold
30,078
– – 0.25% 181
2024
Q2 		$310K Buy
30,078
+20,377
+210% +$210K 0.15% 224
2024
Q1 		$103K Sell
9,701
-666
-6% -$5.66K 0.05% 359
2023
Q4 		$94.7K Buy
10,367
+2,623
+34% +$22.6K 0.06% 386
2023
Q3 		$80.3K Sell
7,744
-771
-9% -$10.6K 0.05% 360
2023
Q2 		$122K Buy
+8,515
New +$98.2K 0.07% 328
2022
Q4 		– Sell
-16,847
Closed -$187K – 476
2022
Q3 		$187K Buy
16,847
+121
+0.7% +$1.15K 0.07% 326
2022
Q2 		$141K Buy
16,726
+8,151
+95% +$83.8K 0.05% 329
2022
Q1 		$117K Sell
8,575
-505
-6% -$8.16K 0.05% 273
2021
Q4 		$179K Buy
9,080
+2,930
+48% +$69K 0.07% 250
2021
Q3 		$197K Sell
6,150
-326
-5% -$10.8K 0.09% 272
2021
Q2 		$219K Sell
6,476
-277
-4% -$9.92K 0.09% 279
2021
Q1 		$254K Buy
6,753
+118
+2% +$4.94K 0.11% 285
2020
Q4 		$220K Buy
6,635
+393
+6% +$15.9K 0.09% 336
2020
Q3 		$229K Sell
6,242
-834
-12% -$28.9K 0.12% 282
2020
Q2 		$233K Buy
+7,076
New +$272K 0.11% 324

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Virtus ETF Advisers's PHAT Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Phathom Pharmaceuticals (PHAT) in Q1 2025, closing a stake of 43,789 shares — an estimated $356K sold.

Virtus ETF Advisers first reported a position in PHAT in Q2 2020 and held it in 17 quarters. The position peaked at $544K in Q3 2024. 137 funds tracked by Wall St. Rank hold PHAT as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Phathom Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 43,789 Phathom Pharmaceuticals shares in Q1 2025, an estimated $356K.
  • Virtus ETF Advisers first reported a position in Phathom Pharmaceuticals in Q2 2020 and held it in 17 quarters.
  • Virtus ETF Advisers's Phathom Pharmaceuticals position peaked at $544K in Q3 2024.
  • 137 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.